Capricor Therapeutics (CAPR) to Release Earnings on Wednesday

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Capricor Therapeutics to post earnings of ($0.31) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The firm had revenue of $4.91 million during the quarter, compared to the consensus estimate of $10.00 million. Capricor Therapeutics had a negative return on equity of 231.68% and a negative net margin of 89.72%. On average, analysts expect Capricor Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Capricor Therapeutics Price Performance

Shares of CAPR stock traded up $0.20 on Tuesday, hitting $3.97. 377,771 shares of the stock traded hands, compared to its average volume of 351,246. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $8.22. The firm has a 50 day simple moving average of $4.89 and a two-hundred day simple moving average of $5.12. The firm has a market cap of $126.96 million, a price-to-earnings ratio of -4.74 and a beta of 4.00.

Analyst Upgrades and Downgrades

A number of research firms have commented on CAPR. Oppenheimer started coverage on Capricor Therapeutics in a report on Friday, May 17th. They set an “outperform” rating and a $14.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, May 14th. StockNews.com cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, July 2nd. Finally, LADENBURG THALM/SH SH lifted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $21.75.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.